Abstract: Growing evidences show that matrix metalloproteinase-1 (MMP1) plays important roles in tumorigenesis and cancer metastasis. The interactions between MMP1−1607 1G.2G polymorphism and risk of gastric cancer (GC) have been reported, but results remained ambiguous. To determine the association between MMP1−1607 1G.2G polymorphism and risk of GC, we conducted a meta-analysis and identified the outcome data from all the research papers estimating the association between MMP1−1607 1G.2G polymorphism and GC risk, which was based on comprehensive searches using databases such as PubMed, Elsevier Science Direct, Excerpta Medica Database (EMBASE), and Chinese National Knowledge Infrastructure (CNKI). The fixed-effects model was used in this meta-analysis. Data were extracted, and pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. In this meta-analysis, six studies involving 1,377 cases and 1,543 controls were included. We identified the significant association between MMP1−1607 1G.2G polymorphism and GC risk for allele model (OR =1.05; 95% CI, 1.01−1.08), for dominant model (OR =1.11; 95% CI, 1.08−1.15), and for recessive model (OR =1.06; 95% CI, 0.98−1.14). In summary, our analysis demonstrated that MMP1−1607 1G.2G polymorphism was significantly associated with an increased risk of GC.
Introduction
Gastric cancer (GC) is the fourth most common cancer and second leading cause of cancer-related deaths worldwide. 1 The mechanism of gastric carcinogenesis remains elusive. Environmental and genetic factors possibly play a role in the etiology of the disease. 2, 3 However, these risk factors cannot fully explain the development of GC, since only a minority of exposed population finally developed GC, indicating possible interplay between risk factors and personal background including genetic susceptibility. 4 Matrix metalloproteinases (MMPs) are a group of proteolytic enzymes involved in physiological and pathological extracellular matrix processing, capable of degrading essentially all extracellular matrix components. 5, 6 MMPs are divided into five structural families, including collagenases, gelatinases, stromelysins, matrilysins, and membrane-type MMPs. More evidence indicates that many MMPs are involved in tumorigenesis by modulating cell proliferation, apoptosis, and angiogenesis. 7 MMP1, located on 11q22.3, is one member of the MMP family and degrades interstitial collagen types I, II, and III. The expression level of MMP1 gene is at low level in normal cells under physiological conditions; 8, 9 however, MMP1 expression is dramatically increased in many malignancies. 5, 10 It has been reported that the promoter of MMP1 can regulate MMP1 gene transcription, in which there is a functional single nucleotide polymorphism (SNP), MMP1−1607 1G.2G (rs1799750), 11, 12 which contains a guanine insertion/deletion polymorphism at position −1607 13 and leads to higher expression of MMP1. In the current study, we performed a meta-analysis of hospital-based studies to determine the association between the MMP1−1607 1G.2G polymorphism and GC risk.
Materials and methods study strategy
A systematic computerized search in all the electronic databases that could search for literatures, including PubMed, Chinese National Knowledge Infrastructure (CNKI), EMBASE and Elsevier Science Direct etc, was conducted to collect all casecontrol studies evaluating MMP1 and GC in humans published until August 2014. The search was developed without any language restriction and searching for the following terms: (matrix metalloproteinase-1 OR MMP1), (polymorphism OR polymorphisms OR variant OR variants OR genotype), and (cancer OR carcinoma OR neoplasm). To expand our research, we also performed the search in the CNKI database using terms in Chinese, such as MMP1, gastric cancer risk OR GC risk, and polymorphism. The references for all identified publications were hand-searched for additional studies.
statistical methods
We used odds ratios (ORs) and 95% confidence intervals (CIs) to measure the strength of association between MMP1−1607 1G>2G polymorphism and GC risk. Pooled ORs and 95% CIs were calculated for an allele mode, a dominant model (variant homozygote + heterozygote vs wild-type homozygote), and a recessive model (variant homozygote vs heterozygote + wild-type homozygote).
Then, we assessed an estimate of potential publication bias using the funnel plot, in which the standard error of log (SEL) of every study was plotted against its log (OR), and an asymmetric plot indicated a potential publication bias. We assessed funnel plot asymmetry using Egger's linear regression test, a linear regression method of evaluating funnel plot asymmetry on the natural logarithm scale of the OR. The significance of the intercept was determined using the t-test suggested by Egger, and P,0.05 was considered representative of statistically significant publication bias. All of the statistical tests were performed using STRATA version 12.0 (StrataCorp, College Station, TX, USA).
Data extraction
The following basic data were collected from the studies that met the inclusion criteria: first author's name, tumor type, year of publication, country, ethnicity of study population, number of cases and controls, and genotyping method. Two independent investigators conducted data extraction work, and they resolved discrepancies through discussion. Study qualities were judged according to the criteria modified from a previously published study 14 ( Table S1 ).
Results

eligible study characteristics
A total of 649 publications, all written in English or Chinese and all extracted from the PubMed, MEDILINE, EMBASE, and CNKI databases, were reviewed. Finally, six articles [15] [16] [17] [18] [19] [20] containing six studies, including 1,377 GC cases and 1,543 non-cancer controls were included in the current metaanalysis. A flowchart shows the study selection procedure ( Figure 1 ). The main characteristics of the studies are listed in Table 1 . Sample sizes and MMP1−1607 1G.2G allele and genotype distributions in the studies considered in the present meta-analysis are shown in Table 2 .
Quantitative synthesis
The fixed-effects model is used in the current meta-analysis. The association between the MMP1−1607 1G.2G polymorphism and cancer risk was estimated with the following models: an allele model (2G vs 1G), a dominant model (2G/2G + 1G/2G vs 1G/1G), and a recessive model (2G/2G vs 2G/1G + 1G/1G). The evaluations of the association of MMP1−1607 1G.2G with cancer risk are shown in Table 3 . In the allele model (2G vs 1G), the overall pooled effect showed that the 2G allele was associated with an increased overall cancer risk, compared with the 1G allele (OR =1.05; 95% CI, 1.01-1.08) (Figure 2A ). In the recessive model (2G/2G vs 2G/1G + 1G/1G), the overall pooled effect showed that the 2G/2G homozygote was not associated with an overall cancer risk, compared with the 2G/2G + 1G/1G homozygote (OR =1.06; 95% CI, 0.98-1.14) ( Figure 2B ). In the dominant model (2G/2G + 1G/2G vs 1G/1G), the overall pooled effect demonstrated that the 2G/2G + 1G/2G genotypes were associated with a significantly increased overall cancer risk, compared with the 1G/1G homozygote (OR =1.11; 95% CI, 1.08-1.15) ( Figure 2C ).
heterogeneity analysis
Heterogeneity was assessed using the χ²-based Q-test among studies in the overall comparisons analysis. Heterogeneity was found in the pooling models (P,0.1 in all models); thus, the fixed-effects model was used to produce an extended pool of studies with 95% CIs. No significant heterogeneity can be seen among the six comparisons using the dominant model, recessive model, or allelic contrast. (Figure 3 ). These findings demonstrated that publication bias, if any, did not significantly affect the results of our current meta-analysis for the association between MMP1−1607 and GC risk.
Publication bias
Discussion
MMPs can degrade the extracellular matrix and basement membrane, which is an important event in many physiological and pathological processes, including tumor invasion and metastasis. MMP expression has been found in a variety of human tumors and is significantly correlated with tumor invasion, metastasis, and therapeutic response. 21 However, certain members of the MMP family exert contradicting roles at different stages during cancer progression, depending upon other factors and upon the tumor stage, tumor site, enzyme localization, and substrate profile. 22 The expression level of the MMP1 gene was found to be increased in various tumors and was related to a poor prognosis in several types of cancers. MMP1 expression can be regulated by the MMP1 promoter. The polymorphism at position −1607 among the MMP1 promoters determined the increased MMP1 transcriptional level, which is attributed to its 2G allele generating a core-binding site for the E26 transformation-specific (ETS) transcription factor family, leading to the increased MMP1 expression. 23 There were six articles [15] [16] [17] [18] [19] [20] containing six studies, including 1,377 GC cases and 1,543 non-cancer controls used in the present meta-analysis. The procedure of meta-analysis was performed by using STRATA version 12.0 software. We found that individuals with the 2G allele and 1G/2G + 2G/2G genotypes had a higher risk of GC for all models, including allele and dominant models. Interestingly, in a recessive model, there was no significant difference between 2G/2G genotype and 1G/2G + 1G/1G genotypes. These results indicated that 2G allele and heterozygote 2G might affect the individual's phenotype more than other genotypes; the 2G allele or 1G/2G genotype carriers therefore seemed more susceptible to cancer development than 1G allele genotype carriers, or 1G/1G genotype carriers.
In the past several years, other studies have also found that the 2G allele is associated with an increased risk of other cancers. Zhang et al 12 
2525
MMP1 promotor snP and gastric cancer of lung cancer in Asian, but not in Caucasian subjects. 24 Taken together, the relationship between MMP1 rs1799750 polymorphism and cancer risk may be disease-specific and may depend on other factors, such as race, age, habits, etc. There are another two studies that relate to GC and MMP1, included in Li et al (2013) 25 and Yang et al (2014). 26 Meanwhile, Li's study 14, 25 gathered data before August 2011, and Yang's before June 2013. In our results, there are four more studies involved, indicating the advantages of our study compared to previously published similar studies.
Recently, multiple therapeutic agents named matrix metalloproteinase inhibitors (MMPIs) have been developed to target MMPs and to control their enzymatic activity.
22
MMP1−1607 1G.2G polymorphism may be regarded as a target of MMPIs in treatment of GC in the future.
study limitations
There are some limitations to the current study. First, we have collected all eligible studies, but the study number was not large and the numbers of patients examined were small. Second, we did not assess the potential effects of other factors such as differences in race. Third, only one SNP in MMP1 was included in this study. Some other SNPs in MMP1 also could contribute to susceptibility to GC. The effects of these SNPs and the interaction or network among these related genes should also be studied in the future.
Conclusion
In conclusion, our present meta-analysis indicates that MMP1−1607 1G.2G polymorphism is associated with GC risk. However, our results should be further validated with larger samples and in different ethnic populations, due to the limited study numbers and relatively small sample sizes.
Disclosure
The authors report no conflicts of interest in this work.
OncoTargets and Therapy
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/oncotargets-and-therapy-journal OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors. 
